Venomics AI uses a combination of venom biology, high‑throughput electrophysiology, and artificial intelligence to decode and engineer venom‑derived peptides into drug candidates. Their platform processes over 20 million unique bioactive peptides and screens them against more than 100 disease‑relevant targets, enabling rapid discovery of therapeutics for areas such as pain, diabetes, and antimicrobial resistance. By leveraging nature’s evolution‑optimized chemistry, they aim to create scalable, precision medicines from venom sources.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug discovery pipelines often struggle to find novel, highly selective molecules, leading to long development timelines and high failure rates, especially for emerging challenges such as antimicrobial resistance and metabolic disorders.
Solution
Venomics AI combines venom biology, high‑throughput electrophysiology, and artificial‑intelligence‑driven analysis to rapidly decode and screen millions of bioactive peptides from diverse venom sources. The platform automates the progression from venom extraction through electrophysiological screening, AI‑based hit identification, and chemical synthesis, delivering candidate therapeutics for more than 100 disease‑relevant targets. By leveraging the evolutionary optimization of venom peptides, Venomics AI generates molecules with inherent potency and selectivity, accelerating the creation of new antibiotics, non‑opioid analgesics, and metabolic disease agents. The end‑to‑end pipeline produces data‑rich candidate dossiers that can be handed off to partner pharmaceutical companies for preclinical and clinical development.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking novel, high‑affinity biologics for antimicrobial, pain‑management, and metabolic indications, as well as contract research organizations that require rapid hit generation and candidate optimization.
Features
- Access to a library of over 20 million unique venom‑derived peptides spanning a broad phylogenetic spectrum
- High‑throughput electrophysiology platform that measures peptide activity across multiple target classes in a single run
- AI models that prioritize hits for potency, selectivity, and developability, reducing manual triage time
- Automated synthesis workflow that converts selected peptide sequences into scalable drug candidates
- Integrated analytics linking peptide structure to functional outcomes, enabling rational engineering of antimicrobial, analgesic, and metabolic agents
- Capability to target more than 100 disease‑relevant proteins, including those implicated in antibiotic resistance and diabetes/weight‑loss pathways